Chorioretinal Ischemia and Angiogenic Milieu Following Photodynamic Therapy

REFERENCES

• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992;99:933–943.
   PubMed Web of Science ®Google Scholar
• Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205–210.
   PubMed Web of Science ®Google Scholar
• Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–1642.
   Google Scholar
• Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132–1142.
   Google Scholar
• Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049–1061.
   Google Scholar
• Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448–457.
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy Report 2. Am J Ophthalmol. 2001; 131: 541–560.
   PubMed Web of Science ®Google Scholar
• Ferrario A, von Tiehl KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066–4069.
   PubMed Web of Science ®Google Scholar
• Jiang F, Zhang ZG, Katakowski M, et al. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol. 2004;79:494–498.
   Google Scholar
• Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: Effects of fluence rate. Br J Cancer. 1998;77:1386–1394.
   Google Scholar
• Engbrecht BW, Menon C, Kachur AV, et al. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 1999;59:4334–4342.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473–4480.
   PubMed Web of Science ®Google Scholar
• Starita C, Hussain AA, Pagliarini S, et al. Hydrodynamics of aging Bruch’s membrane: Implications for macular disease. Exp Eye Res. 1996;62:565–572.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Hariprasad SM, DuPont J, et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998;39:385–390.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005;46:1033–1038.
   PubMed Web of Science ®Google Scholar
• Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: Angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384–2391.
   PubMed Web of Science ®Google Scholar
• Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina. 2007;27:713–723.
   Google Scholar
• Arteel GE, Thurman RG, Yates JM, et al. Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 1995;72:889–895.
   Google Scholar
• Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998;253:743–750.
   PubMedGoogle Scholar
• Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–868.
   PubMed Web of Science ®Google Scholar
• Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, et al. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2003;44:2192–2198.
   PubMed Web of Science ®Google Scholar
• Gilpin DA. Calculation of a new Meeh constant and experimental determination of burn size. Burns. 1996;22:607–611.
   PubMed Web of Science ®Google Scholar
• Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142:95–104.
   PubMed Web of Science ®Google Scholar
• Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol. 2006;124:815–823.
   Google Scholar
• Huang Z, Chen Q, Shakil A, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol. 2003;78:496–502.
   PubMed Web of Science ®Google Scholar
• Fingar VH, Mang TS, Henderson BW. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice. Cancer Res. 1988;48:3350–3354.
   PubMed Web of Science ®Google Scholar
• Chen B, Xu Y, Agostinis P, et al. Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. Int J Oncol. 2001;18:1279–1285.
   Google Scholar
• Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol. 1999;117:1329–1345.
   PubMed Web of Science ®Google Scholar
• Huang LE, Gu J, Schau M, et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998;95:7987–7992.
   PubMed Web of Science ®Google Scholar
• Chang TC, Huang CJ, Tam K, et al. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J Biol Chem. 2005;280:36567–36574.
   PubMed Web of Science ®Google Scholar
• Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun. 2002;291:908–914.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830–841.
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–757.
   PubMed Web of Science ®Google Scholar
• Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322–2331.
   Web of Science ®Google Scholar
• Ciulla TA, Criswell MH, Snyder WJ, et al. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol. 2005;89:113–119.
   PubMedGoogle Scholar